See related review by Lees *et al.*, <http://ccforum.com/content/13/5/231>

Given the confusion and strong opinions surrounding goal-directed therapy (GDT), Lees and colleagues \[[@B1]\] have done a commendable job of clearly defining GDT and how it pertains to each clinical setting as well as separately examining the individual bodies of relevant literature. The authors separate the physiologic and pathophysiologic discussion of both the perioperative and septic patient populations, thus contextualizing different approaches to both volume and hemodynamic GDT. Despite the encouraging body of literature in the early days of oxygen-targeted approaches to early GDT (oxygen delivery \[DO~2~\] of greater than 600 mL/min per m^2^) \[[@B2]-[@B4]\], more recent studies have not confirmed these results \[[@B5],[@B6]\]. Much speculation and controversy surrounds this technique, where it appears that no benefit, if not worse outcomes, are being observed in patients with established sepsis. Conversely, measurable benefits have been observed in the perioperative setting, though not in all of the published studies.

Recent interest surrounds the work of Rivers and colleagues \[[@B7]\], in which a significant mortality reduction was observed in patients admitted with septic shock to the emergency department. Patients were randomly assigned to either standard-of-care treatment or a multifaceted early GDT algorithm, incorporating volume optimization, blood, and inotropes. Major criticisms of the study are that it was single-center with relatively small numbers and with a high mortality rate in the control group (considering the APACHE II \[Acute Physiology and Chronic Health Evaluation II\] scores), and no subsequent studies have yet replicated these results. A large multicenter randomized controlled study (studying almost 2,000 patients), called the ProCESS (Protocolized Care for Early Septic Shock) Study (ClinicalTrials.gov number NCT00510835), is currently under way, examining this technique in greater detail.

The major controversy in the perioperative setting is whether to maximize stroke volume or to restrict fluids. These bodies of literature appear to be completely contradictory in their techniques, usually leaving the clinician confused. With a number of randomized controlled trials published, there is little doubt that stroke volume optimization is a good thing, albeit that all published studies are single-center efforts \[[@B8]\]. The restrictive studies have all used different strategies for restricting the total volume of fluids administered, with results ranging from improved outcomes through no difference to worse outcomes with restrictive practice \[[@B9],[@B10]\]. It is extremely unfortunate that the name \'restriction\' was chosen early on in this body of literature as the true technique guides a relative fluid restriction to prior techniques rather than an absolute restriction in volume. A more suitable term is \'avoidance of crystalloid excess\', which is the key to improving outcomes. These two approaches can be complementary, when a judicious volume of crystalloid is administered (that is, \'restrictive\' approach) combined with a stroke volume-targeted amount of colloid (\'goal-directed\'), depending on the patient and type of surgery.

This all leaves us wondering what technology we should use. For pure volume optimization, the esophageal Doppler monitor has the largest body of evidence to guide its use \[[@B11]-[@B13]\]. Its relatively steep and difficult learning curve has probably been its Achilles heel, slowing adoption somewhat; however, its incorporation into the Enhanced Recovery After Surgery (ERAS) program is currently a strong driving force for renewed interest. An alternative approach is arterial waveform-derived cardiac output monitoring, in which the intravascular volume responsiveness indices (for example, stroke volume variation and pulse pressure variation) appear to be capable of providing acceptable data for guiding fluid management in mandatory ventilated patients \[[@B14]\]. It is important to note that there are currently only a couple of studies showing that oxygen-targeted approaches \[[@B15]\] or volume optimization \[[@B16]\] with these monitors improves outcomes. The current distinct lack of pertinent research in this area makes difficult any recommendation regarding universal adoption of these waveform-based technologies.

The big question is: what should we do, or how should we go about early GDT? We believe that carefully managed crystalloids, following the \'restrictive\' principles and accounting for crystalloid needs, is the first important step. Early, simple algorithmic, stroke volume-targeted colloid fluid administration is the second important step, guiding both the administration and the pausing of colloid intravenous fluids.

So should we then use oxygen-targeted approaches? Although the groups of Shoemaker \[[@B2]\], Boyd \[[@B3]\], Wilson \[[@B4]\], and Pearse \[[@B15]\] have all shown improved outcomes with these types of approaches, it is the dissention of groups showing no difference or worse outcomes that has clouded the water \[[@B5],[@B6]\]. Despite unfavorable results in patients with advanced sepsis, it is likely that in addition to the above-mentioned fluid management, the high-risk perioperative patient will benefit from such approaches. The target DO~2~of 600 mL/min per m^2^of Shoemaker and colleagues \[[@B2]\] could still be ideal, but it seems prudent to individualize each patient\'s target based on their specific physiologic profile, something we should gain greater understanding of over the next few years, with cardiopulmonary exercise testing driving the type and extent of therapy. Furthermore, we currently have no useful monitor of tissue \'well-being\', which could be invaluable in the delivery of GDT. Tissue oximetry may be of benefit but is still a long way from being a routine monitor.

Clearly, our practice needs to be guided to optimizing tissues at risk (for example, the gut). When these tissues are struggling, our therapy needs to be escalated to meet the need and resuscitate these tissues. Should the risk have endured too long and tissues suffer irreparable damage, the final word belongs to Shoemaker. Following the publication of a large GDT study by Gattinoni and colleagues \[[@B6]\] in 1995, Shoemaker \[[@B17]\] wrote a letter to the editor, stating: \'\...Gattinoni *et al*., like Hayes *et al*., have done us a service by pointing out the limitations of our approach, which clearly does not prevent organ failure and death in patients who already have established organ failure. We concur that it is impossible to resuscitate dead cells and failed organs, even with oxygen\'.
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